NCT05052723: A reported trial by Joseph Kim
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05052723 |
|---|---|
| Title | Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 4, 2022 |
| Completion date | Nov. 5, 2024 |
| Required reporting date | Nov. 5, 2025, midnight |
| Actual reporting date | Nov. 4, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |